Optimer Looks To Partner C. Diff Candidate After Trial Success
This article was originally published in The Pink Sheet Daily
OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.
You may also be interested in...
Optimer Rides High After OPT-80 C. Diff Trial Success
Phase III data show antibiotic non-inferior to Vancocin; additional trial results due mid-2009 with an NDA filing by year’s end.
Forest Vows To Double Pipeline Potential
Firm restates commitment to aclidinium for COPD.
As Cubicin Threats Line Up, Cubist Spells Out A Strategy
Firm seeks new indications, late-stage assets.